Also called personalized medicine, this evolving field makes use of an individual’s genes, lifestyle, environment and other factors to identify unique disease risks and guide treatment decision-making.
Masimo's MightySat Medical is the first FDA-cleared pulse oximeter available to consumers without a prescription, which could disrupt the market for the notoriously inaccurate at-home devices.
MediView’s technologies utilize AR to provide clinicians with 3D “X-ray vision” guidance during minimally invasive procedures and surgeries, while also offering remote collaboration.
Colorado voters legalized physician-assisted suicide for terminally ill patients last November, but the resistance of the state’s Catholic health systems may make aid-in-dying services difficult to access.
A study of a new HIV neutralizing antibody, 10-1074, has completed its testing in humans. Led by Florian Klein, of the University Hospital Cologne and German Center for Infection Research, the research is published in Nature Medicine.
Researchers at the Tisch Cancer Institute at the Icahn School of Medicine at Mount Sinai in New York have completed a phase 3 trial on the effectiveness of a drug on advanced liver cancer.
Drug manufacturers have used money to increase their clout with patient advocacy groups, clinical guidelines and physicians, according to a series of commentaries published in JAMA Internal Medicine.
Tempus and University Hospitals Seidman Cancer Center, part of the Case Comprehensive Cancer Center at Case Western Reserve University­, have formed a partnership to develop genomic data, advanced molecular analysis and clinical decision support tools with the goals of improving research and care.
Disease and infection can move through a hospital, including transmission from one patient to the next one to use the same room. A study, published in The Lancet, recently found that disinfection methods using ultraviolet (UV) light decrease the transmission of infectious diseases by 30 percent.
Patients’ lives can be changed by intensive, one-off procedures, but sometimes it’s the slower, incremental care from a primary care physician that can make the most difference.
CMS finalized a significant policy change when it increased the Medicare payments hospitals receive for performing CCTA exams. What, exactly, does the update mean for cardiologists, billing specialists and other hospital employees?
Stryker, a global medtech company based out of Michigan, has kicked off 2025 with a bit of excitement. The company says Inari’s peripheral vascular portfolio is highly complementary to its own neurovascular portfolio.
RBMA President Peter Moffatt discusses declining reimbursement rates, recruiting challenges and the role of artificial intelligence in transforming the industry.
